This is Part Two in a three-part series of blog posts from an interview that Dr. Alicia Henn, Chief Scientific Officer of BioSpherix, conducted with Dr. Heather O’Leary. Our conversation was edited for length and clarity.
In Part One, Heather told us about why her work is so exciting. Today, Heather talks with us about practical considerations that might limit researchers wanting to keep their cells in low-oxygen.
This is a three-part series of blog posts containing excerpts from an interview that Dr. Alicia Henn, Chief Scientific Officer of BioSpherix, conducted with Dr. Heather Ann O’Leary. Dr. O’Leary has finished up a post-doc in the laboratory of Hal Broxmeyer and is starting up her own lab at Indiana University. Her talk was a highlight of ISSCR 2015 where she reported on a landmark paper published in Cell.  Our conversation was edited for length and clarity.
Leonard Freedman, President of the Global Biological Standards Institute in Washington, D.C. published a paper last year in PLOS Biology which it was calculated that $28 billion is wasted yearly on irreproducible pre-clinical research in the US. In our interview with Dr. Freedman, posted on LinkedIn, he says that while that number became a big focus in the press, that this paper also outlined very achievable fixes for some of the most pervasive problems behind the In Vitro Reproducibility Crisis.
In Part Two, Dr. Henn talked with Dr. Ian Mudway about difficulties in getting publishers and the greater scientific community to embrace his important findings. Here, they discuss overcoming scientific inertia and paradigm shift.
In Part One, Dr. Henn talked with Dr. Ian Mudway about his recent publication , “Quantifying the magnitude of the oxygen artefact inherent in culturing airway cells under atmospheric oxygen versus physiological levels.”
Here, they discuss barriers to change in the scientific community.